May 21 (Reuters) - Moderna (MRNA.O), opens new tab said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine candidate to wait for efficacy data from ...
Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval The most common solicited local adverse event for ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Moderna's decision to withdraw ...
Novavax said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a stand-alone flu vaccine, sending shares of the company down ...
July 1 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday that the European Union drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention ...
Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter trial assessing bezisterim’s impact on neurological symptoms associated with long COVID Key milestone reached ...
CLAIM: A COVID-19 test patent application is dated 2020 but was actually filed in 2015. THE FACTS: The patent application, for a system to determine if someone has a viral infection such as COVID-19, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results